•
Dec 31, 2024

Voyager Therapeutics Q4 2024 Earnings Report

Voyager Therapeutics reported a sharp decline in collaboration revenue for Q4 2024, leading to a significant net loss.

Key Takeaways

Voyager Therapeutics experienced a substantial drop in collaboration revenue in Q4 2024 due to reduced revenue recognition from its Neurocrine and Novartis partnerships. Increased research and development expenses contributed to a net loss of $34.5 million. Despite this, the company maintains a strong cash position and expects its financial runway to last into mid-2027.

Collaboration revenue declined to $6.3 million from $90.1 million in Q4 2023.

Net loss for Q4 2024 was $34.5 million, compared to net income of $56.4 million in Q4 2023.

Research and development expenses increased to $35.6 million, up from $25.8 million in Q4 2023.

Cash and cash equivalents stood at $332.4 million, providing financial stability into mid-2027.

Total Revenue
$6.28M
Previous year: $90.1M
-93.0%
EPS
-$0.59
Previous year: $1.25
-147.2%
Collaboration Revenue Change
-93%
0
Cash and Equivalents
$332M
Previous year: $231M
+44.0%
Total Assets
$393M
Previous year: $351M
+11.9%

Voyager Therapeutics

Voyager Therapeutics

Voyager Therapeutics Revenue by Segment

Forward Guidance

Voyager expects to focus on advancing its gene therapy and anti-tau antibody programs in 2025, with key data readouts anticipated in 2026. The company remains financially stable despite revenue declines.

Positive Outlook

  • Financial runway extended into mid-2027, ensuring funding for key programs.
  • Multiple upcoming IND filings for gene therapy programs in 2025.
  • VY1706 tau silencing therapy demonstrated promising preclinical results.
  • VY7523 anti-tau antibody progressing in clinical trials with expected PET imaging data in 2026.
  • Strong partnerships with Neurocrine and Novartis provide potential future milestone payments.

Challenges Ahead

  • Collaboration revenue declined sharply due to lower milestone payments.
  • Increased R&D expenses contributed to a significant net loss.
  • Operating loss widened due to reduced partnership funding.
  • No major revenue catalysts expected in the short term.
  • Regulatory uncertainties could impact timelines for gene therapy programs.